Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGAV | P06756 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.49 |
| ▸ | PLAU | P00749 | 3/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805214 | 0.83 | FPR2 (0.56) | — | |
| SCHEMBL25356787 | 0.80 | PLA2G10 (0.51) | — | |
| SCHEMBL25356783 | 0.80 | PLA2G10 (0.51) | — | |
| SCHEMBL25357735 | 0.80 | PLA2G10 (0.51) | — | |
| SCHEMBL1093903 | 0.79 | CA2 (0.52) | ITGB1ITGB3ITGA2B | |
| SCHEMBL1093901 | 0.79 | CA2 (0.52) | ITGB1ITGB3ITGA2B | |
| SCHEMBL25358515 | 0.79 | L3MBTL1 (0.45) | ITGB3ITGA2BTPSAB1 | |
| SCHEMBL31369570 | 0.79 | L3MBTL1 (0.45) | ITGB3ITGA2BTPSAB1 | |
| SCHEMBL25358511 | 0.79 | L3MBTL1 (0.45) | ITGB3ITGA2BTPSAB1 | |
| SCHEMBL30404207 | 0.79 | CA2 (0.52) | ITGB1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | ADRA2A 3580/4885ADRA2B 3461/4885ADRA2C 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.